Netarsudil ophthalmic solution (0.02%) is an FDA-approved medication used to treat glaucoma and ocular hypertension. Introduced in December 2017, this therapeutic solution belongs to the class of rho-kinase inhibitors, demonstrating its efficacy in managing these eye conditions. This solution is used to minimize visual field loss caused by primary open-angle glaucoma, a condition marked by progressive optic neuropathy and irreversible loss of optic nerve fibers. This activity explores aspects of netarsudil therapy, including indications, contraindications, adverse events, pharmacokinetics, administration, dosing, warnings, precautions, and monitoring. Emphasizing the significance of accurate treatment regimens, regular follow-up, and enhanced patient compliance, the program targets interprofessional team members involved in the clinical management of glaucoma and ocular hypertension.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/133789
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), General Surgery